Case study: Development of the new GMP plant of 53Biologics
53Biologics strengthens its biopharmaceutical capacity in Spain with a new GMP facility in Valladolid, designed in collaboration with Klinea to meet the highest standards and optimize the production of biological medicines.
A strategic project that consolidates 53Biologics biopharmaceutical capacity in Spain.
Pablo Gutiérrez, CEO of 53Biologics, shares his vision on how collaboration with Klinea contributed to the launch of their new GMP plant in Valladolid. A strategic project that strengthens their capacity for the development of biological drugs in Spain.
Conceptual design up to the highest standards
One of the key points of the project was the conceptual design of the new facility. As Gutiérrez points out, “The conceptual design of a GMP facility is crucial to the success of clinical trials.”
Klinea brought its expertise in pharmaceutical engineering to define a design that not only complies with current regulations, but also meets the technical challenges of a modern biopharmaceutical plant.
Innovation and space optimization
The project included the design of a pilot plant in the basement of 53Biologics current building, a major challenge that required making maximum use of the available space without compromising functionality or safety.
Gutiérrez highlights that “Klinea has successfully optimized the use of space to enhance our production capabilities efficiently.”
This solution allows the company to increase its clinical batch production capacity without the need to significantly expand its infrastructure.
Production and quality control, seamlessly integrated
In GMP projects, properly integrating production and quality control areas is one of the greatest challenges. In this case, “Klinea ensured proper area segregation, guaranteeing both operational efficiency and regulatory compliance,” says Gutiérrez.
Thanks to this approach, a smooth and safe workflow has been achieved, which is essential for the smooth operation of the new plant.
A partnership based on trust and specialization
Gutiérrez also emphasizes what he believes made the difference: “their international experience, specialization in biopharma, and personalized approach.”
From day one, the collaboration was based on mutual trust, close communication and a clear focus on results.
Designing the future
With the new 53Biologics plant, has not only expanded its production capacity but also taken a step forward in positioning itself as a European benchmark in the development and manufacturing of biological drugs.
“This project is an investment in the future that will allow us to be more competitive and respond more swiftly to the needs of our clients,” concludes Gutiérrez.
For more information: https://youtu.be/zTcZgRyypVQ